NCT Supports First Study of a Novel TCR-T Cell Therapy – Clinical Trial to Begin in 2027

Advanced, hard-to-treat cancers are among the leading causes of death worldwide—second only to cardiovascular diseases. While CAR-T cell therapies have already shown remarkable success in treating blood and lymphatic cancers, comparable immunotherapy approaches for solid tumors—such as those in the lungs, bladder, soft tissue, or head and neck—have so far yielded significantly less effective results.

The NCT is now supporting a new therapeutic approach with great potential. The multicenter ToMA4TA1 trial will, for the first time, test a newly developed TCR-T cell therapy in patients with advanced solid tumors. The study will include up to 24 participants and aims to evaluate the therapy’s safety, optimal dosing, and initial signs of efficacy. It is coordinated by NCT Berlin. The study will be led by PD Dr. Antonia Busse, senior physician at the Department of Hematology, Oncology, and Tumor Immunology at Charité – Universitätsmedizin Berlin.

The NCT sites in Dresden with the team of Prof Martin Wermke, Heidelberg, SouthWest, WERA, and West, as well as the Nuremberg Hospital as an external partner are involved.

This study is the result of years of research funded by the Federal Ministry for Research, Technology and Space (BMFTR), the Max Delbrück Center for Molecular Medicine (MDC), and the Berlin Institute of Health at Charité (BIH). The clinical trial is made possible through NCT’s newly allocated funding, with a projected start in 2027.

Further information: https://nct.dkfz.de/en/nct/news/news-detail/nct-supports-first-study-of-a-novel-tcr-t-cell-therapy.html